Biosimilar Bevacizumab Matches Avastin in Treating Retinopathy of Prematurity

October 14, 2025

A new study reveals Stivant, a bevacizumab biosimilar, matches Avastin in safety and efficacy for treating retinopathy of prematurity in infants.

FDA Approves Celltrion Aflibercept Biosimilar: Eydenzelt

October 13, 2025

Real-World Stability Confirmed for Biosimilar Ximluci in Prefilled Syringes

October 09, 2025

Review Identifies Gaps in Evidence on Biosimilar DMARD Use During Pregnancy

October 09, 2025

Global Biosimilars Market Sees Gains in Access and Pipeline Expansion

October 07, 2025

BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars

April 21st 2025

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.

Biosimilar and Biologic Use Increasing in Greek Patients With IBD

April 19th 2025

By Deana Ferreri, PhD

Article

A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.

The Top 5 Biosimilar Articles for the Week of April 14

April 18th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 14, 2025.

Trastuzumab Biosimilar Adoption Increased in Japan Due to Reimbursement

April 17th 2025

By Cameron Santoro

Article

Trastuzumab biosimilars saw significant market uptake in Japan after reimbursement incentives were implemented, but bevacizumab biosimilars did not experience a similar response.

President Trump Signs Executive Order to Bring Down Drug Prices

April 16th 2025

By Skylar Jeremias

Article

To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.

How State Substitution Laws Shape Insulin Biosimilar Adoption

April 15th 2025

By Skylar Jeremias

Article

States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.

Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets

April 14th 2025

By Skylar Jeremias

Article

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.

The Global Biosimilar Development and Approval of Yesintek With Elena Wolff-Holz, MD

April 13th 2025

By Cameron Santoro

Video

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety data while noting challenges in global patient recruitment and regulatory navigation.

Experts Pressure Congress to Remove Roadblocks for Biosimilars

April 12th 2025

By Skylar Jeremias

Article

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.

The Top 5 Biosimilar Articles for the Week of April 7

April 11th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 7, 2025.